View : 28 Download: 0

Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis

Title
Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis
Authors
Park J.-H.Kim D.-S.Cho Y.-J.Kim Y.-J.Jeong S.-Y.Lee S.-M.Cho S.-J.Yun C.-W.Jo I.Nam J.-H.
Ewha Authors
조인호
SCOPUS Author ID
조인호scopus
Issue Date
2009
Journal Title
Vaccine
ISSN
0264-410XJCR Link
Citation
vol. 27, no. 13, pp. 1974 - 1983
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
Coxsackievirus B3 (CVB3) is a common agent of viral myocarditis, a major cause of sudden cardiac death, and ultimately dilated cardiomyopathy. However, there is no vaccine in clinical use. In this study, we identified the conserved amino acid sequences in the C-terminal region of the VP2 of the coxsackievirus B group and some echoviruses. The mutant virus, YYFF, with phenylalanines substituted for two tyrosines in these conserved sequences was highly attenuated in vivo and could induce a high neutralizing antibody titer and a cytotoxic T-lymphocyte response against CVB3. Thereby, mutant-virus-immunized mice showed a 100% survival rate and protection against inflammation of the heart and pancreas after lethal dose challenge. Thus, this mutant virus is a good candidate for an attenuated CVB3 vaccine. © 2009 Elsevier Ltd. All rights reserved.
DOI
10.1016/j.vaccine.2009.01.008
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE